Reperfusion therapies remain the only useful therapeutic measure in acute ischemic stroke. However, the efficacy of these measures is highly time-dependent, and due to the need of neuroimaging (CT or MRI) to differentiate between ischemic and hemorrhagic stroke, impossible to be performed at the pre-hospital level from a global perspective. The present project aims to set-up a point-of-care (POC) device to validate a biomarker panel differentiating ischemic and hemorrhagic stroke at the pre-hospital level using a blood sample. Secondary, we aimed to validate a second biomarker panel for the early identification of patients with proximal occlusions, which are candidates for new therapies such as mechanical thrombectomy. During this project, we will recruit 300 patients' cohort with pre-hospital blood samples to validate a 3-biomarker panel to differentiate ischemic and hemorrhagic stroke, and a 2-biomarker panel to identify large vessel occlusion. Point-of-care devices will be set-up in our center during the study period, and new markers to enrich both panels will be evaluated by proteomics. At the end of the enrolment, the future clinical use of this device which will be evaluated by conducting a pilot clinical trial of extra-hospital thrombolysis with tenecteplase (TNK). The implementation of such device represents a revolution in the stroke field, as it would allow to initiate much faster pre-hospital reperfusion therapies without neuroimaging tests. In addition, the mentioned test could be used in low and middle income countries, where neuroimaging is not widely available, as a feasible tool to indicate reperfusion therapies.
Biomarcadores
Ictus
POC
TNK
Ictus hemorrágico
Ictus isquémico
Acción Estratégica en Salud (AES)
01/01/2020 - 31/12/2021
MONTANER VILLALONGA, JOAN
FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA
INSTITUTO DE BIOMEDICINA DE SEVILLA - IBIS
ANDALUCIA
SEVILLA
177,100 €